Value of 18F-FDG-PET/CT and 131I-WBS in the detection of differentiated thyroid cancer progression
Thyroid World Congress ePoster Library. Garbuzov P. 06/21/19; 272129; 32
Petr Garbuzov
Petr Garbuzov
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

Purpose: to compare the diagnostic efficacy of 18F-FDG-PET/CT and 131I-whole body scintigraphy (WBS) in the detecting of differentiated thyroid cancer (DTC) progression. Material and Methods: the results of 120 18F-FDG-PET/CT and 120 131I-WBS studies in 82 DTC patients. 18F-FDG-PET/CT performed on a positron emission tomograph combined with a 16-slice computer tomograph. Post-therapeutic 131I-WBS (after 33-135 mCi) performed during each course of radioiodine therapy on the single-detector gamma camera. Results.18F-FDG-PET/CT has a high sensitivity in detecting tumor progression(89%) and superior to 131I-WBS,p <0.001. The predictive value of the negative result of 18FDG-PET/CT in 62% significantly exceeds that of 131I-WBS in 34%. Therefore, in the negative 18F-FDG-PET/CT, progression can be more confidently rejected than in the negative 131I-WBS result. The predictive value of the positive result of 18F-FDG-PET/CT and 131I-WBS was similar - 92% and 95%,respectively. Therefore, according to the positive results of 18F-FDG-PET/CT and 131I-WBS, it is possible to assert with the same certainty the presence of progression. The following types of tumor progression were identified: in 34%-isolated locoregional recurrence, in 36%-isolated distant metastasis, in 30,5% -a combination of locoregional recurrence with distant metastases. The sensitivity of 18F-FDG-PET/CT in detecting all types of progression was quite high without statistically significant difference,p>0.05. For 131I-WBS isolated distant metastasis is best reveals then other types of recurrence(p <0.05). 18F-FDG-PET/CT superior to 131I-WBS in the diagnosis of all three types of progression,p <0.05. Conclusion.The inclusion of 18F-FDG-PET/CT in the diagnostic algorithm of DTC patients during the monitoring of combined treatment allows to detect or exclude the presence of metastatic foci in 87% and to change the tactics of treatment and follow-up in 49% of cases. 


Purpose: to compare the diagnostic efficacy of 18F-FDG-PET/CT and 131I-whole body scintigraphy (WBS) in the detecting of differentiated thyroid cancer (DTC) progression. Material and Methods: the results of 120 18F-FDG-PET/CT and 120 131I-WBS studies in 82 DTC patients. 18F-FDG-PET/CT performed on a positron emission tomograph combined with a 16-slice computer tomograph. Post-therapeutic 131I-WBS (after 33-135 mCi) performed during each course of radioiodine therapy on the single-detector gamma camera. Results.18F-FDG-PET/CT has a high sensitivity in detecting tumor progression(89%) and superior to 131I-WBS,p <0.001. The predictive value of the negative result of 18FDG-PET/CT in 62% significantly exceeds that of 131I-WBS in 34%. Therefore, in the negative 18F-FDG-PET/CT, progression can be more confidently rejected than in the negative 131I-WBS result. The predictive value of the positive result of 18F-FDG-PET/CT and 131I-WBS was similar - 92% and 95%,respectively. Therefore, according to the positive results of 18F-FDG-PET/CT and 131I-WBS, it is possible to assert with the same certainty the presence of progression. The following types of tumor progression were identified: in 34%-isolated locoregional recurrence, in 36%-isolated distant metastasis, in 30,5% -a combination of locoregional recurrence with distant metastases. The sensitivity of 18F-FDG-PET/CT in detecting all types of progression was quite high without statistically significant difference,p>0.05. For 131I-WBS isolated distant metastasis is best reveals then other types of recurrence(p <0.05). 18F-FDG-PET/CT superior to 131I-WBS in the diagnosis of all three types of progression,p <0.05. Conclusion.The inclusion of 18F-FDG-PET/CT in the diagnostic algorithm of DTC patients during the monitoring of combined treatment allows to detect or exclude the presence of metastatic foci in 87% and to change the tactics of treatment and follow-up in 49% of cases. 


    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings